Cargando…

pS2 and response to adjuvant hormone therapy in primary breast cancer.

We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, partic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spyratos, F., Andrieu, C., Hacène, K., Chambon, P., Rio, M. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968674/ https://www.ncbi.nlm.nih.gov/pubmed/8297741

Ejemplares similares

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer
por: Gupta, S., et al.
Publicado: (2018)

Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer [Response To Letter]
por: Wako, Zerko, et al.
Publicado: (2022)

pS2 is an independent factor of good prognosis in primary breast cancer.
por: Thompson, A. M., et al.
Publicado: (1993)

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices
por: Shaikh, Asim Jamal, et al.
Publicado: (2012)

Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy
por: Kate, Anahita, et al.
Publicado: (2016)

Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
por: Luqmani, Y. A., et al.
Publicado: (1993)

Correction: Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2023)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer
por: Bhatta, Sumita S, et al.
Publicado: (2013)

Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer
por: Tan, Ern-Yu, et al.
Publicado: (2022)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy
por: Kinsey-Trotman, Stephen, et al.
Publicado: (2016)

Adjuvant hormonal therapy for stage I endometrial cancer
por: Gien, L., et al.
Publicado: (2008)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Controversies in the hormonal adjuvant therapy of postmenopausal patients
por: Dowsett, M
Publicado: (2009)

Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials
por: Abrial, Catherine, et al.
Publicado: (2009)

Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer [Letter]
por: Bekele, Firomsa
Publicado: (2021)

The Development of Schematics to Illustrate Women’s Experiences with Adjuvant Hormone Therapy in the Treatment of Breast Cancer
por: AlOmeir, Othman, et al.
Publicado: (2022)

Assessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice
por: Camejo, Natalia, et al.
Publicado: (2023)

Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction
por: Park, Jung Youl, et al.
Publicado: (2018)

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.
por: Bouchet, C., et al.
Publicado: (1998)

Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study
por: Broët, P, et al.
Publicado: (1999)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Interactions between Alcohol Consumption and Adjuvant Hormone Therapy in Relation to Breast Cancer-Free Survival
por: Kowalski, Allison, et al.
Publicado: (2018)

Pain and Menopause Symptoms of Breast Cancer Patients with Adjuvant Hormonal Therapy in Korea: Secondary Analysis
por: Yi, Myungsun, et al.
Publicado: (2018)

Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening
por: He, Wei, et al.
Publicado: (2019)

Effect of Adjuvant Hormonal Therapy on the Development of Pulmonary Fibrosis after Postoperative Radiotherapy for Breast Cancer
por: Anzic, Mitja, et al.
Publicado: (2020)

Comparison of a new microplate oestrogen receptor (ER) enzyme immunoassay with other ER detection methods.
por: Delage, V., et al.
Publicado: (1997)

A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer
por: Barron, T I, et al.
Publicado: (2013)

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
por: MacGrogan, G., et al.
Publicado: (1996)

Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
por: Munster, Pamela N, et al.
Publicado: (2001)

pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.
por: Henry, J. A., et al.
Publicado: (1991)

The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients
por: Taketani, Kenji, et al.
Publicado: (2013)

Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review
por: Moon, Zoe, et al.
Publicado: (2017)

Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
por: Zeng, Erwei, et al.
Publicado: (2022)

Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
por: Marsigliante, S., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_siridlp39soj5u7o2kitq81vqn